Disagree big here. Standard of care is statin treatment. No IRB would approve a study without having statin on board. You mention statin intolerant patients can be enrolled. That is a small number of patients and would thus be harder to study. This study is robust in its design and will absolutely be set to succeed. Read the literature out on EPA and this is high dose EPA in an unhealthy population. last year another article out showing EPA ability to reduce ACS. There's so much literature out there on its benefits it's overwhelming.
Ralphey, as large as the statin market is, I am guessing there are a lot more people who are statin-tolerant, than are statin-intolerant. Would you agree or disagree?
News 
Market Data 
Discover 
